Implantable device for sustained release of a macromolecular drug compound
An implantable device for delivery of a macromolecular drug compound is provided. The device comprises a core having an outer surface and a membrane layer positioned adjacent to the outer surface of the core. The core comprises a core polymer matrix within which is dispersed a drug compound having a molecular weight of about 0.5 kDa or more, the polymer matrix containing a hydrophobic polymer. Further, the membrane layer comprises a membrane polymer matrix within which the macromolecular drug compound is optionally dispersed. The concentration of the macromolecular drug compound in the core is greater than the concentration of the macromolecular drug compound in the membrane layer.
1. An implantable device for delivery of a macromolecular drug compound, the device comprising: a core having an outer surface, wherein the core comprises a core polymer matrix within which is dispersed a drug compound having a molecular weight of about 5 kDa or more, the polymer matrix containing a first ethylene vinyl acetate copolymer; and a membrane layer positioned adjacent to the outer surface of the core, wherein the membrane layer comprises a membrane polymer matrix within which the macromolecular drug compound is optionally dispersed, wherein the concentration of the macromolecular drug compound in the core is greater than the concentration of the macromolecular drug compound in the membrane layer, the membrane polymer matrix comprising a second ethylene vinyl acetate copolymer, wherein the second ethylene vinyl acetate copolymer constitutes from about 70 wt. % to about 99 wt. % of the membrane layer, and wherein the implantable device has a release rate between 0.1E+0 and 0.5E+2 μg per hour for a time period up to about 1500 hours.
2. The implantable device of claim 1 , wherein the device has a circular cross-sectional shape.
3. The implantable device of claim 2 , wherein the device has a diameter of from about 0.5 to about 50 millimeters.
4. The implantable device of claim 1 , wherein the device is in the form of a cylinder.
5. The implantable device of claim 1 , wherein the device is in the form of a disc.
6. The implantable device of claim 1 , wherein macromolecular drug compounds constitute from about 5 wt. % to about 60 wt. % of the core and the core polymer matrix constitutes from about 40 wt. % to about 95 wt. % of the core.
7. The implantable device of claim 1 , wherein after a time period of 30 days, the device exhibits a cumulative release ratio of the macromolecular drug compound of from about 40% to about 85%.
8. The implantable device of claim 1 , wherein the first ethylene vinyl acetate copolymer has a vinyl acetate monomer content of about 10 wt. % to about 45 wt. % of the copolymer.
9. The implantable device of claim 1 , wherein the second ethylene vinyl acetate copolymer has a vinyl acetate monomer content of about 10 wt. % to about 45 wt. % of the copolymer.
10. The implantable device of claim 1 , wherein the first ethylene vinyl acetate copolymer has a melting temperature of from about 40° C. to about 140° C. as determined in accordance with ASTM D3418-15.
11. The implantable device of claim 1 , wherein the first ethylene vinyl acetate copolymer has a melt flow index of from about 0.2 to about 100 grams per 10 minutes as determined in accordance with ASTM D1238-13 at a temperature of 190° C. and a load of 2.16 kilograms.
12. The implantable device of claim 1 , wherein the macromolecular drug compound is a protein, peptide, enzyme, antibody, interferon, interleukin, blood factor, vaccine, nucleotide, lipid, or a combination thereof.
13. The implantable device of claim 1 , wherein the membrane layer is free of the macromolecular drug compound.
14. The implantable device of claim 1 , wherein the ratio of the concentration of the macromolecular drug compound in the core to the concentration of the macromolecular drug compound in the membrane layer is about 1.5 or more.
15. The implantable device of claim 1 , wherein the ratio of the melt flow index of the first ethylene vinyl acetate copolymer in the core to the melt flow index of the second ethylene vinyl acetate copolymer in the membrane layer is from about 1 to about 20, as determined in accordance with ASTM D1238-13 at a temperature of 190° C. and a load of 2.16 kilograms.
16. The implantable device of claim 1 , wherein the membrane polymer matrix also contains a hydrophilic compound.
17. The implantable device of claim 16 , wherein the hydrophilic compound includes a hydrophilic polymer.
18. The implantable device of claim 17 , wherein the hydrophilic polymer includes a sodium, potassium or calcium alginate, carboxymethylcellulose, agar, gelatin, polyvinyl alcohol, polyalkylene glycol, collagen, pectin, chitin, chitosan, poly-1-caprolactone, polyvinylpyrrolidone, poly(vinylpyrrolidone-co-vinyl acetate), polysaccharide, hydrophilic polyurethane, polyhydroxyacrylate, dextran, xanthan, hydroxypropyl cellulose, methylcellulose, protein, ethylene vinyl alcohol copolymer, water-soluble polysilane, water-soluble silicone, water-soluble polyurethane, or a combination thereof.
19. The implantable device of claim 1 , wherein the core, membrane layer, or both contain a radiocontrast agent.
20. The implantable device of claim 1 , further comprising a second membrane layer positioned adjacent to an outer surface of the membrane layer.
21. A method for treating a condition, disease, and/or cosmetic state of a patient, the method comprising subcutaneously implanting the device of claim 1 in a patient.